{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"disease":["Colorectal Neoplasms","Colorectal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2266355"],"location":["United States"],"study_start_month":["7"],"keyword":["Sirolimus"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Nab-rapamycin in Combo With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer","description":"A phase 1/2 multi-center investigation of ABI-009 (nab-rapamycin) in combination with mFOLFOX6 and Bevacizumab as first-line therapy in patients with advanced or metastatic colorectal cancer","dates":{"creation":"2018-07-15"},"accession":"2266355","cross_references":{"ClinicalTrials___gov":["NCT03439462"]}}